Suven Life announces Phase-3 narcolepsy study at SLEEP-2026
Suven Life announces Phase-3 narcolepsy study at SLEEP-2026 — Suven Life Sciences will present three posters on Samelisant (SUVN-G3031), including global Phase-3 data from the AWAKE study in narcolepsy, at the SLEEP-2026 Annual Meeting. The presentations highlight key clinical advancements for its lead candidate. This boosts visibility among global researchers and potential partners. Regulatory approval could open a $1.2B market opportunity in sleep disorders.
📊 STOCKS: SUVENLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #ClinicalTrial
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →